{"gene":"BRD2","run_date":"2026-06-09T22:02:45","timeline":{"discoveries":[{"year":2008,"finding":"BRD2 (and BRD3) associate preferentially with hyperacetylated chromatin along the entire lengths of transcribed genes, enriched in H4K5ac, H4K12ac, and H3K14ac marks, and allow RNA polymerase II to transcribe through nucleosomes in a defined in vitro transcription system dependent on specific histone H4 modifications. BRD2 also has intrinsic histone chaperone activity.","method":"ChIP-seq, defined in vitro transcription reconstitution assay, histone modification analysis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro transcription system with defined components, combined with ChIP and histone modification analyses; multiple orthogonal methods in a single rigorous study","pmids":["18406326"],"is_preprint":false},{"year":2006,"finding":"Crystal structure of the N-terminal bromodomain (BD1) of human BRD2 reveals a homodimer in solution and in the crystal, with two acetyllysine-binding pockets and a negatively charged secondary pocket at the dimer interface; BRD2 BD1 specifically recognizes histone H4 tail acetylated at Lys12 (H4K12ac).","method":"X-ray crystallography, biochemical dimerization assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with independent biochemical validation of dimer formation; replicated and extended by a follow-up structural study (PMID:20048151)","pmids":["17148447"],"is_preprint":false},{"year":2010,"finding":"Crystal structures of BRD2 BD1 in complex with three different H4K12ac peptides show that BD1 recognizes the H4 tail acetylated at Lys12, while hypoacetylated Lys8 of H4 binds at the dimer interface cavity; mutation of Lys8 in the H4K12ac peptide decreases binding to BRD2 BD1, establishing Lys8 as critical for recognition.","method":"X-ray crystallography, binding/mutagenesis studies","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution co-crystal structures with mutagenesis validation; independent replication of BD1 homodimer and H4K12ac specificity from prior study","pmids":["20048151"],"is_preprint":false},{"year":2000,"finding":"RING3/BRD2 is a nuclear serine-threonine kinase that transactivates promoters of cell cycle regulatory genes (cyclin D1, cyclin A, cyclin E, DHFR) dependent on E2F binding sites and Ras signaling; a kinase-deficient point mutant fails to transactivate; nuclear extracts co-purify E2F-1 and E2F-2 with RING3 by immunoaffinity and recombinant protein affinity chromatography; Rb overexpression suppresses RING3-dependent transactivation.","method":"Transient transfection reporter assays, kinase-dead mutagenesis, immunoaffinity chromatography, epistasis with Rb overexpression","journal":"Cell growth & differentiation","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — kinase-dead mutagenesis combined with affinity co-purification of E2F complex and Rb epistasis; multiple orthogonal methods in one study","pmids":["10965846"],"is_preprint":false},{"year":2000,"finding":"RING3/BRD2 is constitutively nuclear in proliferating HeLa cells but is delocalized in serum-starved fibroblasts and undergoes activation-induced nuclear translocation upon serum stimulation; site-directed mutagenesis of a monopartite classical nuclear localization sequence abolishes both nuclear translocation and transcriptional activity at E2F-dependent promoters.","method":"Immunostaining, confocal microscopy, site-directed mutagenesis of NLS, reporter transactivation assays","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct localization experiment with functional consequence, NLS mutagenesis linking localization to transcriptional activity; multiple orthogonal methods","pmids":["10934046"],"is_preprint":false},{"year":1999,"finding":"RING3/BRD2 (ET domain) physically interacts with KSHV latent nuclear antigen (LANA); this interaction results in phosphorylation of serine/threonine residues in the C-terminal region of LANA (aa 951–1107); RING3 is not itself a kinase but recruits an unidentified serine/threonine kinase into the complex.","method":"Yeast two-hybrid, co-immunoprecipitation, deletion mapping, phosphorylation assay","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping and functional phosphorylation readout; single lab, two complementary methods","pmids":["10559289"],"is_preprint":false},{"year":2005,"finding":"BRD2 mediates recruitment of E2F-1/E2F-2 and histone H4-directed acetyltransferase activity to the cyclin A promoter in S-phase; ChIP shows BRD2 physically occupies the cyclin A promoter and its overexpression increases H4 acetylation at that promoter; BRD2-containing complexes contain E2F-1 and histone H4 acetyltransferase activity.","method":"Chromatin immunoprecipitation (ChIP), co-immunoprecipitation, histone acetyltransferase assay, overexpression/cell cycle analysis","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating promoter occupancy, HAT activity in immunopurified complex, cell-cycle phenotype with cyclin A overexpression; multiple orthogonal methods in one study","pmids":["15548137"],"is_preprint":false},{"year":2006,"finding":"BRD2 is a TBP-associated protein; the first bromodomain contains a 26 amino acid peptide essential for BRD2-TBP interaction; serum stimulation induces formation of a BRD2-E2F-1-TBP ternary complex, with BRD2 required for TBP recruitment to E2F-1-responsive promoters.","method":"Co-immunoprecipitation, deletion/peptide mapping, luciferase reporter assays, overexpression","journal":"Molecular and cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — reciprocal Co-IP with domain mapping and functional reporter assays; single lab","pmids":["17111193"],"is_preprint":false},{"year":2003,"finding":"Lymphoid-restricted overexpression of BRD2 in Eμ-BRD2 transgenic mice drives B-cell lymphoma with increased cyclin A transcription; both wild-type and kinase-null BRD2 transgenes produce lymphomagenesis, indicating kinase activity is dispensable but BRD2-mediated recruitment of E2F factors and histone acetyltransferase to the cyclin A promoter is the mechanistic basis.","method":"Transgenic mouse model, kinase-dead mutant transgene, cyclin A transcription analysis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase-dead transgene epistasis in vivo establishing mechanism independent of kinase activity; single lab, in vivo model with clear phenotypic readout","pmids":["14563639"],"is_preprint":false},{"year":2009,"finding":"Brd2 is required for embryogenesis and neural tube closure; homozygous Brd2-null embryos die by E11.5 with neural tube defects and exencephaly; Brd2 is highly expressed in the developing neural tube; Brd2-deficient embryos cannot be rescued by wild-type extraembryonic tissues, indicating an embryo-autonomous requirement.","method":"Knockout mouse generation, tetraploid complementation, in situ hybridization, cell proliferation assays","journal":"Developmental dynamics / Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent knockout studies with tetraploid complementation control; replicated across two labs (PMID:19301389 and PMID:19362612)","pmids":["19301389","19362612"],"is_preprint":false},{"year":2012,"finding":"Brd2 is required for cell cycle exit and neuronal differentiation in neuroepithelial cells; Brd2 deficiency accelerates cell cycle progression and impairs differentiation; genetic removal of E2F1 in Brd2-deficient mice rescues the neuronal differentiation and cell cycle abnormalities, placing Brd2 upstream of E2F1 in neuronal development.","method":"Transgene-insertion knockout, Brd2;E2F1 double-mutant genetic epistasis, cell cycle and differentiation marker analysis","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in double-mutant rescue experiment directly placing BRD2 upstream of E2F1; clean loss-of-function phenotype with molecular pathway placement","pmids":["22885183"],"is_preprint":false},{"year":2012,"finding":"Brd2 is recruited to chromatin through a combination of hyperacetylated H4 (via its bromodomains) and additional features of the histone variant H2A.Z; Brd2 co-purifies preferentially with H2A.Z-containing nucleosomes and is required for androgen receptor (AR)-regulated gene expression in an H2A.Z-dependent manner.","method":"Nucleosome purification/mass spectrometry, co-immunoprecipitation, ChIP, chemical inhibition with cell-based reporter","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — biochemical purification with MS, ChIP, and functional chemical inhibition; single lab, multiple orthogonal methods","pmids":["23144632"],"is_preprint":false},{"year":2013,"finding":"BRD2 and BRD4 physically associate with the promoters of inflammatory cytokine genes (e.g., IL-6, TNF-α) in macrophages; Brd2 hypomorphic mice show impaired proinflammatory cytokine production; siRNA knockdown and the BET inhibitor JQ1 independently abrogate macrophage inflammatory responses.","method":"ChIP, genetic hypomorph model, siRNA knockdown, small-molecule inhibitor (JQ1), in vivo LPS challenge","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP at cytokine promoters, genetic model, independent siRNA and pharmacological validation; multiple orthogonal methods replicated across genetic and pharmacological approaches","pmids":["23420887"],"is_preprint":false},{"year":2013,"finding":"The C-terminal domain of Brd2 is required for chromatin association; bromodomains and the C-terminal domain contribute equally to transcription and alternative splicing regulation; Brd2 regulates ~1450 genes transcriptionally and ~290 genes at the level of alternative splicing; live-cell FRAP imaging quantified Brd2 domain contributions to chromatin binding kinetics.","method":"Genome-wide screen (transcriptome), siRNA depletion, FRAP live-cell imaging, co-immunoprecipitation, domain deletion analysis","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FRAP with domain deletions, Co-IP, genome-wide transcriptome; single lab, multiple orthogonal methods","pmids":["24048450"],"is_preprint":false},{"year":2017,"finding":"BRD2 co-localizes genome-wide with the architectural protein CTCF; CTCF recruits BRD2 to co-bound sites (BRD2 dispensable for CTCF occupancy); BRD2 depletion weakens topological domain boundaries co-occupied by CTCF and BRD2 (Hi-C), and allows regulatory influence to spread between adjacent genes (single-molecule FISH); BRD4 does not co-localize with CTCF.","method":"ChIP-seq, Hi-C, single-molecule mRNA FISH, BRD2 depletion, site-specific CTCF disruption","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genome-wide ChIP-seq, Hi-C, and single-molecule FISH with depletion; multiple orthogonal methods in one study","pmids":["28388437"],"is_preprint":false},{"year":2017,"finding":"Brd2 associates with the chromatin insulator CTCF and the cohesin complex to support cis-regulatory enhancer assembly during Th17 cell differentiation; Brd2 binds the transcription factor Stat3 in an acetylation-sensitive manner and facilitates Stat3 recruitment to active enhancers occupied by Irf4 and Batf; Brd4 controls RNA Pol II processivity via cyclin T1/Cdk9 recruitment and Pol II Ser2 phosphorylation—distinct from Brd2's role.","method":"ChIP-seq, Co-IP (acetylation-sensitive), Th17 differentiation model with genetic depletion, Pol II Ser2 phosphorylation assay","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq with Co-IP and Pol II phosphorylation assays, replicated independently in same year by complementary study; multiple orthogonal methods in one lab","pmids":["28262505"],"is_preprint":false},{"year":2022,"finding":"BRD2 promotes spatial mixing and A/B compartmentalization of active chromatin after cohesin loss; this activity requires BRD2's double bromodomain (acetylated target recognition) and its low-complexity domain (binding partners); BRD4 and cohesin antagonize BRD2 binding to chromatin; polymer simulation supports a BRD2-cohesin interplay model for nuclear topology.","method":"Hi-C (cohesin depletion), live-cell imaging, domain mutant analysis, polymer simulation, ChIP-seq","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — Hi-C, live imaging, domain mutagenesis, and polymer modeling; multiple orthogonal methods in one rigorous study","pmids":["35410381"],"is_preprint":false},{"year":2016,"finding":"H2A.Z.1 monoubiquitylation (H2A.Z.1ub) antagonizes BRD2 at bivalent gene promoters in ESCs; loss of monoubiquitylation results in BRD2 gain at de-repressed promoters, and BRD2 inhibition restores gene silencing at these sites, establishing an antagonistic relationship between H2A.Z.1ub and BRD2 in regulating transcriptional balance at bivalent genes.","method":"H2A.Z.1(K3R3) mutant ESCs, quantitative proteomics, BRD2 ChIP, BRD2 inhibitor rescue experiments","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — quantitative proteomics, ChIP, and pharmacological rescue in a defined genetic mutant; multiple orthogonal methods","pmids":["26804911"],"is_preprint":false},{"year":2017,"finding":"BRD2 is spatially recruited to DNA double-strand breaks (DSBs) via its tandem bromodomains binding to H4 acetylation generated by Tip60/KAT5; BRD2 binding protects H4Ac from deacetylases and allows acetylation to spread ~2 kb flanking the DSB; BRD2 facilitates ZMYND8 recruitment to flanking chromatin, limits L3MBTL1 repressor binding, and promotes 53BP1 binding while limiting end-resection.","method":"ChIP at DSBs (laser damage), BRD2 domain mutant analysis, ZMYND8/53BP1 co-localization, bromodomain mutant rescue","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP at DSBs with domain mutants and functional downstream readouts; single lab, multiple orthogonal approaches","pmids":["29018219"],"is_preprint":false},{"year":2018,"finding":"HDAC11 suppresses the brown adipose tissue thermogenic program through physical association with BRD2; HDAC11 catalytic activity is required for this suppression and the mechanism depends on BRD2 interaction, as demonstrated by co-immunoprecipitation and cell-based assays.","method":"HDAC11 knockout mice, co-immunoprecipitation, cell-based transcriptional assays, ex vivo BAT analysis","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP with knockout phenotype and functional dependence on catalytic activity; single lab, two orthogonal methods","pmids":["30089714"],"is_preprint":false},{"year":2019,"finding":"LYAR binds BRD2 through a mechanism not requiring acetyl-lysine-binding bromodomains and recruits BRD2 to rDNA promoters and transcribed regions via upstream binding factor (UBF); BRD2 is required for recruitment of the MYST-type acetyltransferase KAT7 to rDNA, resulting in enhanced local H4 acetylation and increased rRNA synthesis.","method":"Co-immunoprecipitation, ChIP-qPCR at rDNA, siRNA knockdown, histone acetylation analysis","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP with ChIP and knockdown functional readout; single lab, two orthogonal methods","pmids":["31504794"],"is_preprint":false},{"year":2022,"finding":"BRD2 is required for ACE2 transcription in human lung epithelial cells and cardiomyocytes; BRD2 inhibition reduces endogenous ACE2 expression and blocks SARS-CoV-2 infection in human cells and Syrian hamsters; BRD2 also controls transcription of interferon-stimulated genes induced upon SARS-CoV-2 infection.","method":"Targeted CRISPRi screen, BRD2 pharmacological inhibition (ABBV-744), qRT-PCR, viral infection assay, in vivo hamster model","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPRi screen with pharmacological validation in vitro and in vivo; multiple orthogonal approaches across cell types and animal model","pmids":["35027731"],"is_preprint":false},{"year":2014,"finding":"BRD2 is the critical BET family mediator of STAT5 transcriptional activity; BRD2 knockdown (but not BRD3 or BRD4) selectively reduces STAT5-dependent (not STAT3-dependent) gene expression in leukemia cells; BRD2 knockdown synergizes with tyrosine kinase inhibitors in inducing apoptosis in STAT5-driven leukemia models.","method":"siRNA knockdown of individual BET proteins, STAT5 reporter assays, gene expression analysis, cell viability/apoptosis assays","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — isoform-specific siRNA knockdown distinguishing BRD2 from BRD3/BRD4, functional STAT5 reporter; single lab, two orthogonal methods","pmids":["24435449"],"is_preprint":false},{"year":2009,"finding":"Whole-body disruption of Brd2 causes severe obesity with pancreatic islet expansion and hyperinsulinemia but enhanced glucose tolerance; Brd2 normally inhibits beta-cell mitosis and insulin transcription; in adipocytes, Brd2 co-represses PPARγ and inhibits adipogenesis; Brd2 knockdown protects adipocytes from TNF-α-induced insulin resistance.","method":"Brd2 knockout mice, 3T3-L1 adipocyte knockdown, insulin secretion assay, metabolic phenotyping","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout and cell-based knockdown with defined metabolic phenotype; single lab, two cellular systems","pmids":["19883376"],"is_preprint":false},{"year":2013,"finding":"BRD2 directly binds the cyclin A promoter in primary B cells (ChIP); forced Brd2 expression in B cells expands the B cell compartment and increases cyclin A mRNA/protein levels and S-phase progression in mitogen-stimulated B cells but not T cells; BRD2 is also required for hematopoiesis as shown by Brd2-specific knockdown.","method":"Lentiviral overexpression in HSCs with reconstitution, ChIP at cyclin A promoter, siRNA knockdown, cell cycle analysis","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with in vivo reconstitution model and knockdown; single lab, two orthogonal methods","pmids":["24319289"],"is_preprint":false},{"year":2013,"finding":"A compound (1a) functions as a molecular glue degrader that drives interaction between BRD2/4 and the E3 ligase adaptor DCAF16 to promote BRD2/4 ubiquitination and degradation; CRISPR knockout of DCAF16 abolishes compound activity.","method":"CRISPR/Cas9 knockout screen of >1000 ligase genes, Co-IP of BRD2/4 with DCAF16, cellular degradation assays","journal":"ACS chemical biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR screen with Co-IP validation demonstrating compound-induced BRD2-DCAF16 interaction; single lab, two orthogonal methods","pmids":["36656921"],"is_preprint":false},{"year":2013,"finding":"NMR spectroscopy identified a specific binding site for the ET domains of BRD2 (and BRD4) on KSHV kLANA C-terminal domain; functional studies show oligomerization of kLANA CTD, the basic patch, and the ET binding site are all required for LANA nuclear speckle formation and latent replication.","method":"NMR spectroscopy, X-ray crystallography of LANA CTD, kLANA deletion/point mutants in functional replication and speckle assays","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR-identified binding site combined with crystal structure and mutagenesis/functional validation; multiple orthogonal methods in one study","pmids":["24146614"],"is_preprint":false},{"year":2005,"finding":"The C-terminal chromatin-binding domain of KSHV LANA-1 is required for interaction with Brd2/RING3, and this same domain is required for LANA-1 functions including binding and replication of viral episomal DNA, transcriptional modulation, and chromatin interaction; deletion mutant analysis maps the minimal interaction region.","method":"LANA-1 deletion mutants, Co-IP, episomal replication assay, transcription reporter assay","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — systematic deletion mapping with Co-IP and multiple functional readouts; single lab","pmids":["16227282"],"is_preprint":false},{"year":2006,"finding":"BRD2/RING3 (via ET domain) and BRD4S delay S-phase entry (G1 arrest) and increase cyclin E promoter activity when ectopically expressed; KSHV LANA-1 directly interacts with BRD4S C-terminal ET domain and partly releases cells from BRD4S- and BRD2/RING3-induced G1 arrest while reducing BRD4S-mediated cyclin E promoter activity.","method":"Ectopic expression in epithelial and B-cell lines, cell cycle FACS, cyclin E promoter reporter assay, Co-IP/domain mapping","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — reporter assays and FACS cell-cycle analysis with Co-IP; single lab, two orthogonal approaches","pmids":["16928768"],"is_preprint":false},{"year":2018,"finding":"BRD2 is required for IFN-stimulated H2A.Z eviction at ISG promoters; BRD2 (and GCN5) depletion blocks IFN-driven H2A.Z removal, impairs ISGF3 recruitment, and reduces ISG mRNA expression and antiviral immunity; BRD2 involvement is distinct from INO80 and SWI/SNF.","method":"siRNA knockdown of BRD2/GCN5/INO80/SWI-SNF, ChIP for H2A.Z and ISGF3, ISG mRNA quantification, viral infection assay","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific siRNA knockdown with ChIP and functional antiviral readout; single lab, multiple orthogonal methods","pmids":["30240626"],"is_preprint":false},{"year":2020,"finding":"BRD2 cooperates with acetylated ELK4 (acetylated at K125) to regulate LAMB3 transcription in colorectal cancer; ELK4 K125 acetylation enhances its interaction with BRD2; JQ1 disrupts ELK4-BRD2 interaction and reduces BRD2 binding to the LAMB3 promoter.","method":"Co-IP with acetylation mutants, ChIP at LAMB3 promoter, JQ1 treatment, mutagenesis of ELK4 K125","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP with acetylation mutagenesis and ChIP; single lab, two orthogonal methods","pmids":["32398865"],"is_preprint":false},{"year":2020,"finding":"BRD2 silencing (but not BRD3 or BRD4) specifically averts sigma-2 receptor (S2R) up-regulation induced by cholesterol deprivation; endogenous BRD2 co-immunoprecipitates with the transcription-active N-terminal half of SREBP2; ChIP-qPCR shows co-occupancy of BRD2, H3K27ac, and SREBP2 at the S2R gene promoter, revealing a BRD2/SREBP2 cooperative transcriptional mechanism.","method":"Isoform-specific siRNA knockdown, Co-IP, ChIP-qPCR","journal":"Life science alliance","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — isoform-specific knockdown, Co-IP, and ChIP; single lab, three complementary methods","pmids":["33234676"],"is_preprint":false},{"year":2022,"finding":"BRD2 is required for TAF3-mediated RNA Pol II initiation at promoters with low H3K4me3 and for R-loop suppression during Pol II elongation; BRD2 and BRD3 function additively, independently, or antagonistically at different promoters; BRD2 also regulates genes critical for embryoid body differentiation by promoter priming in ESCs.","method":"Acute BRD2 protein degradation (auxin-inducible degron), ChIP-seq, quantitative proteomics, R-loop assay, BRD2/BRD3 single and double depletion","journal":"Cellular and molecular life sciences","confidence":"High","confidence_rationale":"Tier 2 / Moderate — acute protein degradation with genome-wide ChIP-seq and proteomics plus R-loop assay; multiple orthogonal methods in one study","pmids":["35665862"],"is_preprint":false},{"year":2017,"finding":"During pluripotent exit, Brd4 downregulation facilitates enhanced Brd2 occupancy at Nodal gene regulatory elements (NREs); Brd2 (not Brd4) is specifically required for differentiative Nodal-Smad2 signaling; BET proteins engage NREs to promote Nodal signaling and Smad2 developmental responses.","method":"Small-molecule screen, ChIP at NREs, targeted BRD2/BRD4 depletion, Smad2 activation assays","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — ChIP with isoform-specific depletion and Smad2 functional readout; single lab","pmids":["28588073"],"is_preprint":false},{"year":2020,"finding":"BRD2 promotes drug resistance in adult T-cell lymphoblastic lymphoma via the RasGRP1/Ras/ERK signaling pathway; BRD2 and E2F1 co-occupy the RasGRP1 promoter (ChIP), and BRD2 suppresses doxorubicin-induced apoptosis both in vitro and in vivo.","method":"ChIP at RasGRP1 promoter, Ras pull-down assay, overexpression/knockdown, xenograft model","journal":"Cancer communications","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — ChIP and Ras activation assay with in vivo xenograft; single lab, two orthogonal methods","pmids":["32459053"],"is_preprint":false},{"year":2024,"finding":"Phosphocreatine (PCr) stabilizes BRD2 by inhibiting poly-ubiquitination; PCr outcompetes the E3 ubiquitin ligase SPOP for BRD2 binding, preventing SPOP-mediated BRD2 degradation; disruption of PCr biosynthesis by cyclocreatine leads to BRD2 degradation and decreased transcription of BRD2 target genes involved in chromosome segregation.","method":"Co-IP (BRD2-SPOP interaction), ubiquitination assay, cyclocreatine treatment, BRD2 stability assay, mouse GBM models","journal":"Cancer discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with ubiquitination assay and in vivo tumor model; single lab, two orthogonal biochemical methods","pmids":["38563585"],"is_preprint":false},{"year":2013,"finding":"Brd2 inhibits adipogenesis via the ERK1/2 signaling pathway; Brd2 overexpression increases ERK1/2 phosphorylation and represses PPARγ/C/EBPα expression; Brd2 knockdown decreases ERK1/2 activity independently of Raf signaling; MEK inhibitor UO126 partly restores adipogenic differentiation in Brd2-overexpressing cells.","method":"Overexpression and siRNA knockdown in 3T3-L1 cells, ERK1/2/JNK/p38 phosphorylation assays, MEK inhibitor epistasis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — gain/loss-of-function with kinase epistasis and MEK inhibitor rescue; single lab","pmids":["24194944"],"is_preprint":false},{"year":2006,"finding":"BRD2 physically interacts with BRD7 in mammalian cells; the region of BRD2 from amino acids 430–798 is critical for BRD2-BRD7 interaction; BRD2 localizes predominantly to the nucleus in diffuse and dotted patterns, with dotted distribution correlating with apoptosis.","method":"Co-immunoprecipitation, subcellular co-localization (GFP), deletion mapping, Hoechst staining","journal":"Molecular and cellular biochemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP with deletion mapping; nuclear localization data correlative for apoptosis, single lab","pmids":["16786191"],"is_preprint":false},{"year":2014,"finding":"The growth factor pleiotrophin (Ptn) antagonizes Brd2 during neuronal differentiation by destabilizing Brd2's association with chromatin; Ptn-Brd2 interaction was identified by co-immunoprecipitation; Ptn knockdown reduces neuronal differentiation, while Ptn overexpression antagonizes Brd2 cell-cycle-stimulating activity.","method":"Co-immunoprecipitation, chromatin fractionation, Ptn knockdown/overexpression, neuronal differentiation assays, spinal cord and neural crest in vivo models","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP with chromatin fractionation and in vivo developmental validation; single lab, two orthogonal methods","pmids":["24695857"],"is_preprint":false},{"year":2020,"finding":"RUNX2 and BRD2 co-immunoprecipitate and both occupy the RANKL promoter; mechanical strain reduces both RUNX2 and BRD2 occupancy at the RANKL promoter (ChIP) and decreases RANKL expression; strain also down-regulates BRD2 expression; RUNX2 knockdown prevents strain-induced RANKL down-regulation.","method":"Co-immunoprecipitation, ChIP at RANKL promoter, four-point bending strain assay, RUNX2 siRNA knockdown","journal":"Gene: X","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP and ChIP with knockdown; single lab, correlative mechanosensing context","pmids":["32550554"],"is_preprint":false},{"year":1998,"finding":"p85/RING3 kinase is activated in multiple organs (lung, kidney, brain, liver, heart) after systemic administration of mitogens (EGF, PMA, IL-1β); anti-RING3 antibodies immunoprecipitate the mitogen-responsive p85 kinase activity from lung and brain, establishing that p85 and RING3 are the same enzyme.","method":"Autophosphorylation membrane assay, kinase immunoprecipitation from tissue lysates","journal":"Oncogene","confidence":"Low","confidence_rationale":"Tier 3 / Weak — immunoprecipitation kinase assay in vivo; single lab, single method establishing identity of p85 with RING3","pmids":["9528865"],"is_preprint":false}],"current_model":"BRD2 is a BET family double-bromodomain protein that reads acetylated histone H4 (preferentially H4K12ac via a homodimeric BD1 structure), associates with hyperacetylated chromatin across transcribed gene bodies, and acts as a transcriptional scaffold by recruiting E2F transcription factors, TBP, and histone acetyltransferases to promote RNA Pol II initiation (via TAF3) and elongation while suppressing R-loops; it co-occupies chromatin with the insulator protein CTCF to enforce topological domain boundaries and compartmentalize the accessible genome, and it coordinates distinct context-specific functions including Th17/Smad2/Nodal signaling, macrophage cytokine gene activation, STAT5-dependent transcription, ACE2/interferon-response gene regulation, DNA double-strand break repair via H4Ac protection, and metabolic gene control in adipocytes and pancreatic β-cells, with its stability regulated by SPOP-mediated ubiquitination (antagonized by phosphocreatine) and its chromatin association modulated by HDAC11, pleiotrophin, and H2A.Z monoubiquitylation."},"narrative":{"mechanistic_narrative":"BRD2 is a BET-family double-bromodomain protein that reads acetylated histone H4 and acts as a chromatin-associated transcriptional scaffold and architectural factor [PMID:18406326, PMID:17148447]. Its N-terminal bromodomain forms a homodimer with two acetyllysine-binding pockets that specifically recognizes H4 acetylated at Lys12, with hypoacetylated Lys8 binding at the dimer interface to complete recognition [PMID:17148447, PMID:20048151]. BRD2 associates along the entire lengths of transcribed genes enriched in H4K5ac/H4K12ac/H3K14ac and enables RNA Pol II to transcribe through nucleosomes in a defined in vitro system, with intrinsic histone chaperone activity [PMID:18406326]; chromatin recruitment also depends on features of the histone variant H2A.Z and is antagonized by H2A.Z.1 monoubiquitylation at bivalent promoters [PMID:23144632, PMID:26804911]. Mechanistically, BRD2 recruits E2F-1/E2F-2 and H4-directed acetyltransferase activity together with TBP to E2F-responsive promoters such as cyclin A to promote cell-cycle gene transcription [PMID:10965846, PMID:15548137, PMID:17111193], and it supports RNA Pol II initiation through TAF3 at promoters with low H3K4me3 while suppressing R-loops during elongation [PMID:35665862]. Independently of transcriptional readout, BRD2 co-localizes genome-wide with the insulator protein CTCF, which recruits it to enforce topological domain boundaries, and it promotes A/B compartmentalization of active chromatin via its double bromodomain and low-complexity domain in an interplay with cohesin and BRD4 [PMID:28388437, PMID:35410381]. BRD2 is required for embryogenesis and neural tube closure, acting upstream of E2F1 to control cell-cycle exit and neuronal differentiation [PMID:19301389, PMID:19362612, PMID:22885183]. Context-specific roles include macrophage inflammatory cytokine gene activation [PMID:23420887], STAT5-dependent leukemic transcription [PMID:24435449], Th17 enhancer assembly through CTCF/cohesin and acetylation-sensitive Stat3 binding [PMID:28262505], ACE2 and interferon-stimulated gene regulation [PMID:35027731, PMID:30240626], recruitment to DNA double-strand breaks where it protects Tip60-generated H4Ac and modulates 53BP1/ZMYND8 [PMID:29018219], and metabolic gene control in adipocytes and pancreatic β-cells [PMID:19883376]. BRD2 protein stability is governed by SPOP-mediated ubiquitination, which phosphocreatine antagonizes by outcompeting SPOP binding [PMID:38563585].","teleology":[{"year":2000,"claim":"Established that RING3/BRD2 functions as a nuclear transcriptional activator of cell-cycle genes coupled to E2F and the Rb/Ras axis, defining its earliest mechanistic role.","evidence":"reporter transactivation, kinase-dead mutagenesis, E2F co-purification and Rb epistasis; NLS mutagenesis with serum-induced nuclear translocation","pmids":["10965846","10934046"],"confidence":"High","gaps":["Whether transactivation requires a genuine intrinsic kinase activity was not resolved structurally","Direct versus scaffold-mediated E2F engagement not distinguished"]},{"year":2005,"claim":"Showed that BRD2 physically occupies the cyclin A promoter and delivers E2F-1 and H4-acetyltransferase activity, converting the genetic link into a chromatin-recruitment mechanism.","evidence":"ChIP at cyclin A promoter, Co-IP, HAT assays in immunopurified complexes, cell-cycle analysis","pmids":["15548137"],"confidence":"High","gaps":["Identity of the associated acetyltransferase not defined in this study","Direct contact surface with E2F not mapped"]},{"year":2006,"claim":"Resolved the structural basis of acetyllysine reading: BD1 is a homodimer that specifically binds H4K12ac, and BRD2 bridges to the basal machinery via TBP.","evidence":"X-ray crystallography of BD1, dimerization assays, reciprocal Co-IP and peptide mapping of BRD2-TBP interaction","pmids":["17148447","17111193"],"confidence":"High","gaps":["Physiological consequence of BD1 dimerization on full-length chromatin binding not addressed","Generality of TBP recruitment beyond E2F promoters unknown"]},{"year":2008,"claim":"Defined the genome-wide chromatin behavior and biochemical readout: BRD2 tracks hyperacetylated transcribed gene bodies and supports Pol II transcription through nucleosomes.","evidence":"ChIP-seq, defined in vitro transcription reconstitution, histone modification analysis","pmids":["18406326"],"confidence":"High","gaps":["Mechanism of intrinsic histone chaperone activity not structurally defined","Functional separation of BRD2 from BRD3 in vivo not established here"]},{"year":2009,"claim":"Demonstrated an essential, embryo-autonomous developmental requirement and connected BRD2's cell-cycle function to neural fate via E2F1.","evidence":"knockout mice with tetraploid complementation, in situ hybridization; later double-mutant E2F1 rescue and metabolic knockout phenotyping","pmids":["19301389","19362612","22885183","19883376"],"confidence":"High","gaps":["Tissue-specific transcriptional targets driving neural tube closure not enumerated","Molecular link between BRD2 loss and metabolic phenotypes incomplete"]},{"year":2012,"claim":"Extended chromatin recruitment beyond H4ac to the histone variant H2A.Z, showing combinatorial targeting that controls specific gene programs.","evidence":"nucleosome purification/MS, Co-IP, ChIP, chemical inhibition; H2A.Z.1 monoubiquitylation mutant ESCs with BRD2 ChIP and inhibitor rescue","pmids":["23144632","26804911"],"confidence":"Medium","gaps":["Direct H2A.Z recognition surface on BRD2 not identified","How monoubiquitylation sterically antagonizes BRD2 binding not resolved"]},{"year":2013,"claim":"Mapped functional domain contributions and broadened BRD2's output to alternative splicing and inflammatory cytokine gene activation in macrophages.","evidence":"FRAP with domain deletions, transcriptome screen, Co-IP; ChIP at cytokine promoters with genetic hypomorph, siRNA and JQ1","pmids":["24048450","23420887","24319289"],"confidence":"High","gaps":["Splicing regulation mechanism (co-transcriptional vs. spliceosome contact) undefined","C-terminal domain binding partners not identified"]},{"year":2017,"claim":"Revealed a non-transcriptional architectural role: BRD2 is recruited by CTCF to enforce topological boundaries and prevent regulatory cross-talk, distinguishing it from BRD4.","evidence":"ChIP-seq, Hi-C, single-molecule FISH with BRD2 depletion and CTCF disruption; Th17 enhancer assembly with cohesin and Stat3","pmids":["28388437","28262505"],"confidence":"High","gaps":["Whether BRD2 stabilizes CTCF/cohesin or acts as an independent insulator not fully separated","Direct CTCF-BRD2 contact surface not mapped"]},{"year":2017,"claim":"Implicated BRD2 in DNA double-strand break repair by reading Tip60-generated H4 acetylation to protect the mark and organize downstream repair factors.","evidence":"ChIP at laser-induced DSBs, bromodomain mutant rescue, ZMYND8/53BP1 co-localization","pmids":["29018219"],"confidence":"Medium","gaps":["Single-lab study without independent replication","Quantitative impact on repair pathway choice not established"]},{"year":2022,"claim":"Unified BRD2's architectural function mechanistically, showing it drives active-compartment mixing through its double bromodomain and low-complexity domain in antagonism with cohesin/BRD4, and elevated its biomedical role to ACE2/ISG control.","evidence":"Hi-C after cohesin depletion, live imaging, domain mutagenesis, polymer simulation; CRISPRi/pharmacological ACE2 and SARS-CoV-2 in vitro and hamster model; auxin-degron ChIP-seq for TAF3/R-loop functions","pmids":["35410381","35027731","35665862"],"confidence":"High","gaps":["How LCD-mediated partner binding integrates with bromodomain reading is not resolved at atomic level","Direct versus indirect control of the ACE2 promoter not fully dissected"]},{"year":2024,"claim":"Identified post-translational control of BRD2 abundance via SPOP-mediated ubiquitination antagonized by phosphocreatine, linking metabolism to BRD2-dependent gene expression.","evidence":"Co-IP of BRD2-SPOP, ubiquitination assays, cyclocreatine treatment, glioblastoma mouse models","pmids":["38563585"],"confidence":"Medium","gaps":["Single-lab biochemistry without independent confirmation","SPOP degron within BRD2 not precisely mapped"]},{"year":null,"claim":"How BRD2 integrates acetyl-lysine reading, H2A.Z recognition, CTCF/cohesin association, and low-complexity-domain interactions into a single recruitment logic that selects between transcriptional, splicing, repair, and architectural outputs remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model couples bromodomain reading to LCD-driven compartmentalization","Rules distinguishing BRD2-specific from BRD3/BRD4 target selection not established","Whether reported context-specific transcription-factor partnerships share a common recruitment mechanism is unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[0,1,2,18]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3,6,7,32]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[3,6,7,14]},{"term_id":"GO:0044183","term_label":"protein folding chaperone","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,37]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[0,14,16]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[20]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,3,6,32]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[3,6,10,24]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0,11,14,16,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[12,15,22,29]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[18]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[9,10,33]}],"complexes":[],"partners":["E2F1","TBP","CTCF","STAT5","STAT3","H2A.Z","SPOP","BRD7"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P25440","full_name":"Bromodomain-containing protein 2","aliases":["O27.1.1"],"length_aa":801,"mass_kda":88.1,"function":"Chromatin reader protein that specifically recognizes and binds histone H4 acetylated at 'Lys-5' and 'Lys-12' (H4K5ac and H4K12ac, respectively), thereby controlling gene expression and remodeling chromatin structures (PubMed:17148447, PubMed:17848202, PubMed:18406326, PubMed:20048151, PubMed:20709061, PubMed:20871596). Recruits transcription factors and coactivators to target gene sites, and activates RNA polymerase II machinery for transcriptional elongation (PubMed:28262505). Plays a key role in genome compartmentalization via its association with CTCF and cohesin: recruited to chromatin by CTCF and promotes formation of topologically associating domains (TADs) via its ability to bind acetylated histones, contributing to CTCF boundary formation and enhancer insulation (PubMed:35410381). Also recognizes and binds acetylated non-histone proteins, such as STAT3 (PubMed:28262505). Involved in inflammatory response by regulating differentiation of naive CD4(+) T-cells into T-helper Th17: recognizes and binds STAT3 acetylated at 'Lys-87', promoting STAT3 recruitment to chromatin (PubMed:28262505). In addition to acetylated lysines, also recognizes and binds lysine residues on histones that are both methylated and acetylated on the same side chain to form N6-acetyl-N6-methyllysine (Kacme), an epigenetic mark of active chromatin associated with increased transcriptional initiation (PubMed:37731000). Specifically binds histone H4 acetyl-methylated at 'Lys-5' and 'Lys-12' (H4K5acme and H4K12acme, respectively) (PubMed:37731000)","subcellular_location":"Nucleus; Chromosome","url":"https://www.uniprot.org/uniprotkb/P25440/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BRD2","classification":"Not Classified","n_dependent_lines":519,"n_total_lines":1208,"dependency_fraction":0.429635761589404},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000204256","cell_line_id":"CID001133","localizations":[{"compartment":"nucleoplasm","grade":3},{"compartment":"nuclear_punctae","grade":2}],"interactors":[{"gene":"PDLIM7","stoichiometry":10.0},{"gene":"DNAJB1","stoichiometry":10.0},{"gene":"DNAJA2","stoichiometry":10.0},{"gene":"SKA3","stoichiometry":4.0},{"gene":"DNAJC7","stoichiometry":4.0},{"gene":"QSER1","stoichiometry":4.0},{"gene":"ERCC6L","stoichiometry":0.2},{"gene":"CSNK2A1","stoichiometry":0.2},{"gene":"CSNK2B","stoichiometry":0.2},{"gene":"HIST2H2BE","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001133","total_profiled":1310},"omim":[{"mim_id":"620524","title":"DDB1- AND CUL4-ASSOCIATED FACTOR 16; DCAF16","url":"https://www.omim.org/entry/620524"},{"mim_id":"618829","title":"NABAIS SA-DE VRIES SYNDROME, TYPE 2; NSDVS2","url":"https://www.omim.org/entry/618829"},{"mim_id":"618828","title":"NABAIS SA-DE VRIES SYNDROME, TYPE 1; NSDVS1","url":"https://www.omim.org/entry/618828"},{"mim_id":"608816","title":"MYOCLONIC EPILEPSY, JUVENILE, SUSCEPTIBILITY TO, 3; EJM3","url":"https://www.omim.org/entry/608816"},{"mim_id":"606462","title":"RAD21 COHESIN COMPLEX COMPONENT; RAD21","url":"https://www.omim.org/entry/606462"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Nuclear speckles","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BRD2"},"hgnc":{"alias_symbol":["KIAA9001","RING3","D6S113E","NAT","FSHRG1"],"prev_symbol":["BRD2-IT1"]},"alphafold":{"accession":"P25440","domains":[{"cath_id":"1.20.920.10","chopping":"76-177","consensus_level":"high","plddt":96.407,"start":76,"end":177},{"cath_id":"1.20.920.10","chopping":"356-450","consensus_level":"high","plddt":97.052,"start":356,"end":450},{"cath_id":"1.20.1270.220","chopping":"635-706","consensus_level":"high","plddt":84.7265,"start":635,"end":706}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P25440","model_url":"https://alphafold.ebi.ac.uk/files/AF-P25440-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P25440-F1-predicted_aligned_error_v6.png","plddt_mean":64.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BRD2","jax_strain_url":"https://www.jax.org/strain/search?query=BRD2"},"sequence":{"accession":"P25440","fasta_url":"https://rest.uniprot.org/uniprotkb/P25440.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P25440/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P25440"}},"corpus_meta":[{"pmid":"23420887","id":"PMC_23420887","title":"BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23420887","citation_count":352,"is_preprint":false},{"pmid":"18406326","id":"PMC_18406326","title":"The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription.","date":"2008","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/18406326","citation_count":304,"is_preprint":false},{"pmid":"25989842","id":"PMC_25989842","title":"BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25989842","citation_count":220,"is_preprint":false},{"pmid":"10559289","id":"PMC_10559289","title":"Latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with RING3, a homolog of the Drosophila female sterile homeotic (fsh) gene.","date":"1999","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/10559289","citation_count":153,"is_preprint":false},{"pmid":"19883376","id":"PMC_19883376","title":"Brd2 disruption in mice causes severe obesity without Type 2 diabetes.","date":"2009","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/19883376","citation_count":144,"is_preprint":false},{"pmid":"12830434","id":"PMC_12830434","title":"BRD2 (RING3) is a probable major susceptibility gene for common juvenile myoclonic epilepsy.","date":"2003","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12830434","citation_count":142,"is_preprint":false},{"pmid":"10965846","id":"PMC_10965846","title":"RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F.","date":"2000","source":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/10965846","citation_count":141,"is_preprint":false},{"pmid":"19301389","id":"PMC_19301389","title":"Double bromodomain-containing gene Brd2 is essential for embryonic development in mouse.","date":"2009","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/19301389","citation_count":130,"is_preprint":false},{"pmid":"16928766","id":"PMC_16928766","title":"Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3-induced G1 cell cycle arrest.","date":"2006","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/16928766","citation_count":129,"is_preprint":false},{"pmid":"12872524","id":"PMC_12872524","title":"Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.","date":"2003","source":"International journal of hygiene and environmental health","url":"https://pubmed.ncbi.nlm.nih.gov/12872524","citation_count":121,"is_preprint":false},{"pmid":"28262505","id":"PMC_28262505","title":"Distinct Roles of Brd2 and Brd4 in Potentiating the Transcriptional Program for Th17 Cell Differentiation.","date":"2017","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/28262505","citation_count":119,"is_preprint":false},{"pmid":"28388437","id":"PMC_28388437","title":"The BET Protein BRD2 Cooperates with CTCF to Enforce Transcriptional and Architectural Boundaries.","date":"2017","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/28388437","citation_count":108,"is_preprint":false},{"pmid":"9367677","id":"PMC_9367677","title":"Identification and characterization of BRDT: A testis-specific gene related to the bromodomain genes RING3 and Drosophila fsh.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9367677","citation_count":99,"is_preprint":false},{"pmid":"15261828","id":"PMC_15261828","title":"Identification of unique, differentiation stage-specific patterns of expression of the bromodomain-containing genes Brd2, Brd3, Brd4, and Brdt in the mouse testis.","date":"2004","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/15261828","citation_count":99,"is_preprint":false},{"pmid":"20183529","id":"PMC_20183529","title":"Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity.","date":"2009","source":"Journal of toxicology and environmental health. Part B, Critical reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20183529","citation_count":98,"is_preprint":false},{"pmid":"22439910","id":"PMC_22439910","title":"Genome-wide analysis of plant nat-siRNAs reveals insights into their distribution, biogenesis and function.","date":"2012","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/22439910","citation_count":98,"is_preprint":false},{"pmid":"16227282","id":"PMC_16227282","title":"Brd2/RING3 interacts with a chromatin-binding domain in the Kaposi's Sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (LANA-1) that is required for multiple functions of LANA-1.","date":"2005","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/16227282","citation_count":97,"is_preprint":false},{"pmid":"17148447","id":"PMC_17148447","title":"Crystal structure of the human BRD2 bromodomain: insights into dimerization and recognition of acetylated histone H4.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17148447","citation_count":95,"is_preprint":false},{"pmid":"20048151","id":"PMC_20048151","title":"Structural basis for acetylated histone H4 recognition by the human BRD2 bromodomain.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20048151","citation_count":94,"is_preprint":false},{"pmid":"14563639","id":"PMC_14563639","title":"E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14563639","citation_count":93,"is_preprint":false},{"pmid":"30089714","id":"PMC_30089714","title":"HDAC11 suppresses the thermogenic program of adipose tissue via BRD2.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/30089714","citation_count":90,"is_preprint":false},{"pmid":"24146614","id":"PMC_24146614","title":"A structural basis for BRD2/4-mediated host chromatin interaction and oligomer assembly of Kaposi sarcoma-associated herpesvirus and murine gammaherpesvirus LANA proteins.","date":"2013","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/24146614","citation_count":89,"is_preprint":false},{"pmid":"18414738","id":"PMC_18414738","title":"The nucleobase-ascorbate transporter (NAT) family: genomics, evolution, structure-function relationships and physiological role.","date":"2008","source":"Molecular bioSystems","url":"https://pubmed.ncbi.nlm.nih.gov/18414738","citation_count":87,"is_preprint":false},{"pmid":"23144632","id":"PMC_23144632","title":"A combination of H2A.Z and H4 acetylation recruits Brd2 to chromatin during transcriptional activation.","date":"2012","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23144632","citation_count":86,"is_preprint":false},{"pmid":"15548137","id":"PMC_15548137","title":"Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A.","date":"2005","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15548137","citation_count":85,"is_preprint":false},{"pmid":"19362612","id":"PMC_19362612","title":"The chromatin-targeting protein Brd2 is required for neural tube closure and embryogenesis.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19362612","citation_count":81,"is_preprint":false},{"pmid":"15316289","id":"PMC_15316289","title":"A novel family of Ca2+/calmodulin-binding proteins involved in transcriptional regulation: interaction with fsh/Ring3 class transcription activators.","date":"2004","source":"Plant molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15316289","citation_count":75,"is_preprint":false},{"pmid":"14980546","id":"PMC_14980546","title":"Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?","date":"2004","source":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","url":"https://pubmed.ncbi.nlm.nih.gov/14980546","citation_count":72,"is_preprint":false},{"pmid":"27008626","id":"PMC_27008626","title":"BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27008626","citation_count":69,"is_preprint":false},{"pmid":"1513324","id":"PMC_1513324","title":"Cloned mouse N-acetyltransferases: enzymatic properties of expressed Nat-1 and Nat-2 gene products.","date":"1992","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/1513324","citation_count":62,"is_preprint":false},{"pmid":"29450199","id":"PMC_29450199","title":"Transfusion-Transmitted Hepatitis E: NAT Screening of Blood Donations and Infectious Dose.","date":"2018","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29450199","citation_count":61,"is_preprint":false},{"pmid":"35027731","id":"PMC_35027731","title":"BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2.","date":"2022","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/35027731","citation_count":60,"is_preprint":false},{"pmid":"36656921","id":"PMC_36656921","title":"CRISPR Screen Reveals BRD2/4 Molecular Glue-like Degrader via Recruitment of DCAF16.","date":"2023","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/36656921","citation_count":60,"is_preprint":false},{"pmid":"24435449","id":"PMC_24435449","title":"Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.","date":"2014","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24435449","citation_count":57,"is_preprint":false},{"pmid":"32398865","id":"PMC_32398865","title":"LAMB3 promotes tumour progression through the AKT-FOXO3/4 axis and is transcriptionally regulated by the BRD2/acetylated ELK4 complex in colorectal cancer.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32398865","citation_count":56,"is_preprint":false},{"pmid":"24048450","id":"PMC_24048450","title":"The C-terminal domain of Brd2 is important for chromatin interaction and regulation of transcription and alternative splicing.","date":"2013","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/24048450","citation_count":55,"is_preprint":false},{"pmid":"26804911","id":"PMC_26804911","title":"H2A.Z.1 Monoubiquitylation Antagonizes BRD2 to Maintain Poised Chromatin in ESCs.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26804911","citation_count":55,"is_preprint":false},{"pmid":"35410381","id":"PMC_35410381","title":"BRD2 compartmentalizes the accessible genome.","date":"2022","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35410381","citation_count":51,"is_preprint":false},{"pmid":"9550404","id":"PMC_9550404","title":"Linkage of LMP, TAP, and RING3 with Mhc class I rather than class II genes in the zebrafish.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9550404","citation_count":51,"is_preprint":false},{"pmid":"11966400","id":"PMC_11966400","title":"The pharmacogenetics of NAT: structural aspects.","date":"2002","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/11966400","citation_count":51,"is_preprint":false},{"pmid":"3209851","id":"PMC_3209851","title":"Linkage of Nat and Es-1 in the mouse and development of strains congenic for N-acetyltransferase.","date":"1988","source":"The Journal of heredity","url":"https://pubmed.ncbi.nlm.nih.gov/3209851","citation_count":50,"is_preprint":false},{"pmid":"10934046","id":"PMC_10934046","title":"Activation-induced nuclear translocation of RING3.","date":"2000","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/10934046","citation_count":49,"is_preprint":false},{"pmid":"11163577","id":"PMC_11163577","title":"Validation and standardisation of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products.","date":"2001","source":"Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology","url":"https://pubmed.ncbi.nlm.nih.gov/11163577","citation_count":49,"is_preprint":false},{"pmid":"29311544","id":"PMC_29311544","title":"Silencing of the lncRNA Zeb2-NAT facilitates reprogramming of aged fibroblasts and safeguards stem cell pluripotency.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29311544","citation_count":49,"is_preprint":false},{"pmid":"11752715","id":"PMC_11752715","title":"Latent nuclear antigen of Kaposi's sarcoma herpesvirus/human herpesvirus-8 induces and relocates RING3 to nuclear heterochromatin regions.","date":"2002","source":"The Journal of general virology","url":"https://pubmed.ncbi.nlm.nih.gov/11752715","citation_count":48,"is_preprint":false},{"pmid":"17111193","id":"PMC_17111193","title":"Brd2 is a TBP-associated protein and recruits TBP into E2F-1 transcriptional complex in response to serum stimulation.","date":"2006","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17111193","citation_count":47,"is_preprint":false},{"pmid":"33849067","id":"PMC_33849067","title":"Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer.","date":"2021","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/33849067","citation_count":45,"is_preprint":false},{"pmid":"10599336","id":"PMC_10599336","title":"Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus.","date":"1999","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/10599336","citation_count":45,"is_preprint":false},{"pmid":"24319289","id":"PMC_24319289","title":"The double bromodomain protein Brd2 promotes B cell expansion and mitogenesis.","date":"2013","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/24319289","citation_count":42,"is_preprint":false},{"pmid":"16516380","id":"PMC_16516380","title":"Association of BRD2 polymorphisms with photoparoxysmal response.","date":"2006","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/16516380","citation_count":41,"is_preprint":false},{"pmid":"31767403","id":"PMC_31767403","title":"Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.","date":"2019","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31767403","citation_count":37,"is_preprint":false},{"pmid":"22885183","id":"PMC_22885183","title":"Brd2 is required for cell cycle exit and neuronal differentiation through the E2F1 pathway in mouse neuroepithelial cells.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22885183","citation_count":36,"is_preprint":false},{"pmid":"30240626","id":"PMC_30240626","title":"Histone H2A.Z Suppression of Interferon-Stimulated Transcription and Antiviral Immunity Is Modulated by GCN5 and BRD2.","date":"2018","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/30240626","citation_count":36,"is_preprint":false},{"pmid":"23497148","id":"PMC_23497148","title":"Rapid birth-and-death evolution of the xenobiotic metabolizing NAT gene family in vertebrates with evidence of adaptive selection.","date":"2013","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/23497148","citation_count":35,"is_preprint":false},{"pmid":"23374712","id":"PMC_23374712","title":"Brd2 gene disruption causes \"metabolically healthy\" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes.","date":"2013","source":"Vitamins and hormones","url":"https://pubmed.ncbi.nlm.nih.gov/23374712","citation_count":33,"is_preprint":false},{"pmid":"30080437","id":"PMC_30080437","title":"JQ1 affects BRD2-dependent and independent transcription regulation without disrupting H4-hyperacetylated chromatin states.","date":"2018","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/30080437","citation_count":33,"is_preprint":false},{"pmid":"24695857","id":"PMC_24695857","title":"Pleiotrophin antagonizes Brd2 during neuronal differentiation.","date":"2014","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/24695857","citation_count":33,"is_preprint":false},{"pmid":"17049203","id":"PMC_17049203","title":"Bromodomain testis-specific protein is expressed in mouse oocyte and evolves faster than its ubiquitously expressed paralogs BRD2, -3, and -4.","date":"2006","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/17049203","citation_count":33,"is_preprint":false},{"pmid":"9373153","id":"PMC_9373153","title":"Chromosomal localization, gene structure and transcription pattern of the ORFX gene, a homologue of the MHC-linked RING3 gene.","date":"1997","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9373153","citation_count":32,"is_preprint":false},{"pmid":"10938964","id":"PMC_10938964","title":"NAT and viral safety in blood transfusion.","date":"2000","source":"Vox sanguinis","url":"https://pubmed.ncbi.nlm.nih.gov/10938964","citation_count":32,"is_preprint":false},{"pmid":"24194944","id":"PMC_24194944","title":"Brd2 inhibits adipogenesis via the ERK1/2 signaling pathway in 3T3-L1 adipocytes.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24194944","citation_count":31,"is_preprint":false},{"pmid":"22225631","id":"PMC_22225631","title":"Apolipoprotein E influences melatonin biosynthesis by regulating NAT and MAOA expression in C6 cells.","date":"2012","source":"Journal of pineal research","url":"https://pubmed.ncbi.nlm.nih.gov/22225631","citation_count":31,"is_preprint":false},{"pmid":"8001235","id":"PMC_8001235","title":"Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells.","date":"1994","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/8001235","citation_count":30,"is_preprint":false},{"pmid":"31504794","id":"PMC_31504794","title":"LYAR potentiates rRNA synthesis by recruiting BRD2/4 and the MYST-type acetyltransferase KAT7 to rDNA.","date":"2019","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/31504794","citation_count":29,"is_preprint":false},{"pmid":"29018219","id":"PMC_29018219","title":"Spatially restricted loading of BRD2 at DNA double-strand breaks protects H4 acetylation domains and promotes DNA repair.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29018219","citation_count":29,"is_preprint":false},{"pmid":"33509905","id":"PMC_33509905","title":"Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma.","date":"2021","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/33509905","citation_count":29,"is_preprint":false},{"pmid":"29608786","id":"PMC_29608786","title":"DNA methylation of the BRD2 promoter is associated with juvenile myoclonic epilepsy in Caucasians.","date":"2018","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/29608786","citation_count":27,"is_preprint":false},{"pmid":"33288543","id":"PMC_33288543","title":"Integration of the Transcriptome and Genome-Wide Landscape of BRD2 and BRD4 Binding Motifs Identifies Key Superenhancer Genes and Reveals the Mechanism of Bet Inhibitor Action in Rheumatoid Arthritis Synovial Fibroblasts.","date":"2020","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/33288543","citation_count":27,"is_preprint":false},{"pmid":"28588073","id":"PMC_28588073","title":"Brd4-Brd2 isoform switching coordinates pluripotent exit and Smad2-dependent lineage specification.","date":"2017","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/28588073","citation_count":25,"is_preprint":false},{"pmid":"32459053","id":"PMC_32459053","title":"BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T-cell lymphoblastic lymphoma.","date":"2020","source":"Cancer communications (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32459053","citation_count":25,"is_preprint":false},{"pmid":"26586120","id":"PMC_26586120","title":"LRP1B, BRD2 and CACNA1D: new candidate genes in fetal metabolic programming of newborns exposed to maternal hyperglycemia.","date":"2015","source":"Epigenomics","url":"https://pubmed.ncbi.nlm.nih.gov/26586120","citation_count":25,"is_preprint":false},{"pmid":"19368118","id":"PMC_19368118","title":"MnSOD genotype and prostate cancer risk as a function of NAT genotype and smoking status.","date":"2009","source":"In vivo (Athens, Greece)","url":"https://pubmed.ncbi.nlm.nih.gov/19368118","citation_count":25,"is_preprint":false},{"pmid":"23665476","id":"PMC_23665476","title":"Identification of ta-siRNAs and cis-nat-siRNAs in cassava and their roles in response to cassava bacterial blight.","date":"2013","source":"Genomics, proteomics & bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/23665476","citation_count":24,"is_preprint":false},{"pmid":"33234676","id":"PMC_33234676","title":"BRD2 regulation of sigma-2 receptor upon cholesterol deprivation.","date":"2020","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/33234676","citation_count":23,"is_preprint":false},{"pmid":"35665862","id":"PMC_35665862","title":"BRD2 interconnects with BRD3 to facilitate Pol II transcription initiation and elongation to prime promoters for cell differentiation.","date":"2022","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/35665862","citation_count":23,"is_preprint":false},{"pmid":"11528504","id":"PMC_11528504","title":"Short tandem repeat (STR) haplotypes in HLA: an integrated 50-kb STR/linkage disequilibrium/gene map between the RING3 and HLA-B genes and identification of STR haplotype diversification in the class III region.","date":"2001","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/11528504","citation_count":23,"is_preprint":false},{"pmid":"21608014","id":"PMC_21608014","title":"The bromodomain-containing gene BRD2 is regulated at transcription, splicing, and translation levels.","date":"2011","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21608014","citation_count":23,"is_preprint":false},{"pmid":"29891831","id":"PMC_29891831","title":"LTBSG1, a New Allele of BRD2, Regulates Panicle and Grain Development in Rice by Brassinosteroid Biosynthetic Pathway.","date":"2018","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/29891831","citation_count":23,"is_preprint":false},{"pmid":"33717143","id":"PMC_33717143","title":"Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33717143","citation_count":22,"is_preprint":false},{"pmid":"35780402","id":"PMC_35780402","title":"Natural variation of the BRD2 allele affects plant height and grain size in rice.","date":"2022","source":"Planta","url":"https://pubmed.ncbi.nlm.nih.gov/35780402","citation_count":22,"is_preprint":false},{"pmid":"37013828","id":"PMC_37013828","title":"Cellular effects of NAT-mediated histone N-terminal acetylation.","date":"2023","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/37013828","citation_count":21,"is_preprint":false},{"pmid":"30938974","id":"PMC_30938974","title":"Small Molecule and Pooled CRISPR Screens Investigating IL17 Signaling Identify BRD2 as a Novel Contributor to Keratinocyte Inflammatory Responses.","date":"2019","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/30938974","citation_count":21,"is_preprint":false},{"pmid":"16857729","id":"PMC_16857729","title":"N-acetyltransferase (Nat) 1 and 2 expression in Nat2 knockout mice.","date":"2006","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/16857729","citation_count":20,"is_preprint":false},{"pmid":"15112318","id":"PMC_15112318","title":"Bromodomain containing 2 (Brd2) is expressed in distinct patterns during ovarian folliculogenesis independent of FSH or GDF9 action.","date":"2004","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/15112318","citation_count":20,"is_preprint":false},{"pmid":"9528865","id":"PMC_9528865","title":"Stimulation of p85/RING3 kinase in multiple organs after systemic administration of mitogens into mice.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9528865","citation_count":19,"is_preprint":false},{"pmid":"32550554","id":"PMC_32550554","title":"Mechanical strain-mediated reduction in RANKL expression is associated with RUNX2 and BRD2.","date":"2020","source":"Gene: X","url":"https://pubmed.ncbi.nlm.nih.gov/32550554","citation_count":19,"is_preprint":false},{"pmid":"29850465","id":"PMC_29850465","title":"Evolution of substrate specificity in the Nucleobase-Ascorbate Transporter (NAT) protein family.","date":"2018","source":"Microbial cell (Graz, Austria)","url":"https://pubmed.ncbi.nlm.nih.gov/29850465","citation_count":19,"is_preprint":false},{"pmid":"38563585","id":"PMC_38563585","title":"Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2.","date":"2024","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38563585","citation_count":18,"is_preprint":false},{"pmid":"33490899","id":"PMC_33490899","title":"Brd2/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation in vitro.","date":"2020","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/33490899","citation_count":18,"is_preprint":false},{"pmid":"16786191","id":"PMC_16786191","title":"BRD2 is one of BRD7-interacting proteins and its over-expression could initiate apoptosis.","date":"2006","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16786191","citation_count":18,"is_preprint":false},{"pmid":"9693039","id":"PMC_9693039","title":"Nucleotide sequence of the ring3 gene in the class II region of the mouse MHC and its abundant expression in testicular germ cells.","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9693039","citation_count":18,"is_preprint":false},{"pmid":"25130458","id":"PMC_25130458","title":"Sex-specific behavioral traits in the Brd2 mouse model of juvenile myoclonic epilepsy.","date":"2014","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/25130458","citation_count":18,"is_preprint":false},{"pmid":"29316078","id":"PMC_29316078","title":"Occult HBV infection in HIV-infected adults and evaluation of pooled NAT for HBV.","date":"2018","source":"Journal of viral hepatitis","url":"https://pubmed.ncbi.nlm.nih.gov/29316078","citation_count":18,"is_preprint":false},{"pmid":"35361883","id":"PMC_35361883","title":"Epigenetic regulation of EIF4A1 through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling in prostate cancer.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35361883","citation_count":17,"is_preprint":false},{"pmid":"15142281","id":"PMC_15142281","title":"NAT gene polymorphisms and susceptibility to Alzheimer's disease: identification of a novel NAT1 allelic variant.","date":"2004","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15142281","citation_count":17,"is_preprint":false},{"pmid":"28604612","id":"PMC_28604612","title":"AA-NAT, MT1 and MT2 Correlates with Cancer Stem-Like Cell Markers in Colorectal Cancer: Study of the Influence of Stage and p53 Status of Tumors.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28604612","citation_count":15,"is_preprint":false},{"pmid":"19487161","id":"PMC_19487161","title":"Two HBV DNA+/HBsAg- blood donors identified by HBV NAT in Shenzhen, China.","date":"2009","source":"Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis","url":"https://pubmed.ncbi.nlm.nih.gov/19487161","citation_count":15,"is_preprint":false},{"pmid":"30300821","id":"PMC_30300821","title":"NF-κB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells.","date":"2018","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/30300821","citation_count":14,"is_preprint":false},{"pmid":"26349765","id":"PMC_26349765","title":"The Epigenetic Reader BRD2 as a Specific Modulator of PAI-1 Expression in Lipopolysaccharide-Stimulated Mouse Primary Astrocytes.","date":"2015","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/26349765","citation_count":14,"is_preprint":false},{"pmid":"34974135","id":"PMC_34974135","title":"O-alkyl and o-benzyl hesperetin derivative-1L attenuates inflammation and protects against alcoholic liver injury via inhibition of BRD2-NF-κB signaling pathway.","date":"2021","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/34974135","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51668,"output_tokens":10423,"usd":0.155674,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20806,"output_tokens":4537,"usd":0.108728,"stage2_stop_reason":"end_turn"},"total_usd":0.264402,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"BRD2 (and BRD3) associate preferentially with hyperacetylated chromatin along the entire lengths of transcribed genes, enriched in H4K5ac, H4K12ac, and H3K14ac marks, and allow RNA polymerase II to transcribe through nucleosomes in a defined in vitro transcription system dependent on specific histone H4 modifications. BRD2 also has intrinsic histone chaperone activity.\",\n      \"method\": \"ChIP-seq, defined in vitro transcription reconstitution assay, histone modification analysis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro transcription system with defined components, combined with ChIP and histone modification analyses; multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"18406326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Crystal structure of the N-terminal bromodomain (BD1) of human BRD2 reveals a homodimer in solution and in the crystal, with two acetyllysine-binding pockets and a negatively charged secondary pocket at the dimer interface; BRD2 BD1 specifically recognizes histone H4 tail acetylated at Lys12 (H4K12ac).\",\n      \"method\": \"X-ray crystallography, biochemical dimerization assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with independent biochemical validation of dimer formation; replicated and extended by a follow-up structural study (PMID:20048151)\",\n      \"pmids\": [\"17148447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Crystal structures of BRD2 BD1 in complex with three different H4K12ac peptides show that BD1 recognizes the H4 tail acetylated at Lys12, while hypoacetylated Lys8 of H4 binds at the dimer interface cavity; mutation of Lys8 in the H4K12ac peptide decreases binding to BRD2 BD1, establishing Lys8 as critical for recognition.\",\n      \"method\": \"X-ray crystallography, binding/mutagenesis studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution co-crystal structures with mutagenesis validation; independent replication of BD1 homodimer and H4K12ac specificity from prior study\",\n      \"pmids\": [\"20048151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"RING3/BRD2 is a nuclear serine-threonine kinase that transactivates promoters of cell cycle regulatory genes (cyclin D1, cyclin A, cyclin E, DHFR) dependent on E2F binding sites and Ras signaling; a kinase-deficient point mutant fails to transactivate; nuclear extracts co-purify E2F-1 and E2F-2 with RING3 by immunoaffinity and recombinant protein affinity chromatography; Rb overexpression suppresses RING3-dependent transactivation.\",\n      \"method\": \"Transient transfection reporter assays, kinase-dead mutagenesis, immunoaffinity chromatography, epistasis with Rb overexpression\",\n      \"journal\": \"Cell growth & differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — kinase-dead mutagenesis combined with affinity co-purification of E2F complex and Rb epistasis; multiple orthogonal methods in one study\",\n      \"pmids\": [\"10965846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"RING3/BRD2 is constitutively nuclear in proliferating HeLa cells but is delocalized in serum-starved fibroblasts and undergoes activation-induced nuclear translocation upon serum stimulation; site-directed mutagenesis of a monopartite classical nuclear localization sequence abolishes both nuclear translocation and transcriptional activity at E2F-dependent promoters.\",\n      \"method\": \"Immunostaining, confocal microscopy, site-directed mutagenesis of NLS, reporter transactivation assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment with functional consequence, NLS mutagenesis linking localization to transcriptional activity; multiple orthogonal methods\",\n      \"pmids\": [\"10934046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"RING3/BRD2 (ET domain) physically interacts with KSHV latent nuclear antigen (LANA); this interaction results in phosphorylation of serine/threonine residues in the C-terminal region of LANA (aa 951–1107); RING3 is not itself a kinase but recruits an unidentified serine/threonine kinase into the complex.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, deletion mapping, phosphorylation assay\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping and functional phosphorylation readout; single lab, two complementary methods\",\n      \"pmids\": [\"10559289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BRD2 mediates recruitment of E2F-1/E2F-2 and histone H4-directed acetyltransferase activity to the cyclin A promoter in S-phase; ChIP shows BRD2 physically occupies the cyclin A promoter and its overexpression increases H4 acetylation at that promoter; BRD2-containing complexes contain E2F-1 and histone H4 acetyltransferase activity.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), co-immunoprecipitation, histone acetyltransferase assay, overexpression/cell cycle analysis\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating promoter occupancy, HAT activity in immunopurified complex, cell-cycle phenotype with cyclin A overexpression; multiple orthogonal methods in one study\",\n      \"pmids\": [\"15548137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BRD2 is a TBP-associated protein; the first bromodomain contains a 26 amino acid peptide essential for BRD2-TBP interaction; serum stimulation induces formation of a BRD2-E2F-1-TBP ternary complex, with BRD2 required for TBP recruitment to E2F-1-responsive promoters.\",\n      \"method\": \"Co-immunoprecipitation, deletion/peptide mapping, luciferase reporter assays, overexpression\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — reciprocal Co-IP with domain mapping and functional reporter assays; single lab\",\n      \"pmids\": [\"17111193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Lymphoid-restricted overexpression of BRD2 in Eμ-BRD2 transgenic mice drives B-cell lymphoma with increased cyclin A transcription; both wild-type and kinase-null BRD2 transgenes produce lymphomagenesis, indicating kinase activity is dispensable but BRD2-mediated recruitment of E2F factors and histone acetyltransferase to the cyclin A promoter is the mechanistic basis.\",\n      \"method\": \"Transgenic mouse model, kinase-dead mutant transgene, cyclin A transcription analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase-dead transgene epistasis in vivo establishing mechanism independent of kinase activity; single lab, in vivo model with clear phenotypic readout\",\n      \"pmids\": [\"14563639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Brd2 is required for embryogenesis and neural tube closure; homozygous Brd2-null embryos die by E11.5 with neural tube defects and exencephaly; Brd2 is highly expressed in the developing neural tube; Brd2-deficient embryos cannot be rescued by wild-type extraembryonic tissues, indicating an embryo-autonomous requirement.\",\n      \"method\": \"Knockout mouse generation, tetraploid complementation, in situ hybridization, cell proliferation assays\",\n      \"journal\": \"Developmental dynamics / Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent knockout studies with tetraploid complementation control; replicated across two labs (PMID:19301389 and PMID:19362612)\",\n      \"pmids\": [\"19301389\", \"19362612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Brd2 is required for cell cycle exit and neuronal differentiation in neuroepithelial cells; Brd2 deficiency accelerates cell cycle progression and impairs differentiation; genetic removal of E2F1 in Brd2-deficient mice rescues the neuronal differentiation and cell cycle abnormalities, placing Brd2 upstream of E2F1 in neuronal development.\",\n      \"method\": \"Transgene-insertion knockout, Brd2;E2F1 double-mutant genetic epistasis, cell cycle and differentiation marker analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in double-mutant rescue experiment directly placing BRD2 upstream of E2F1; clean loss-of-function phenotype with molecular pathway placement\",\n      \"pmids\": [\"22885183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Brd2 is recruited to chromatin through a combination of hyperacetylated H4 (via its bromodomains) and additional features of the histone variant H2A.Z; Brd2 co-purifies preferentially with H2A.Z-containing nucleosomes and is required for androgen receptor (AR)-regulated gene expression in an H2A.Z-dependent manner.\",\n      \"method\": \"Nucleosome purification/mass spectrometry, co-immunoprecipitation, ChIP, chemical inhibition with cell-based reporter\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — biochemical purification with MS, ChIP, and functional chemical inhibition; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"23144632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BRD2 and BRD4 physically associate with the promoters of inflammatory cytokine genes (e.g., IL-6, TNF-α) in macrophages; Brd2 hypomorphic mice show impaired proinflammatory cytokine production; siRNA knockdown and the BET inhibitor JQ1 independently abrogate macrophage inflammatory responses.\",\n      \"method\": \"ChIP, genetic hypomorph model, siRNA knockdown, small-molecule inhibitor (JQ1), in vivo LPS challenge\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP at cytokine promoters, genetic model, independent siRNA and pharmacological validation; multiple orthogonal methods replicated across genetic and pharmacological approaches\",\n      \"pmids\": [\"23420887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The C-terminal domain of Brd2 is required for chromatin association; bromodomains and the C-terminal domain contribute equally to transcription and alternative splicing regulation; Brd2 regulates ~1450 genes transcriptionally and ~290 genes at the level of alternative splicing; live-cell FRAP imaging quantified Brd2 domain contributions to chromatin binding kinetics.\",\n      \"method\": \"Genome-wide screen (transcriptome), siRNA depletion, FRAP live-cell imaging, co-immunoprecipitation, domain deletion analysis\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FRAP with domain deletions, Co-IP, genome-wide transcriptome; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"24048450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BRD2 co-localizes genome-wide with the architectural protein CTCF; CTCF recruits BRD2 to co-bound sites (BRD2 dispensable for CTCF occupancy); BRD2 depletion weakens topological domain boundaries co-occupied by CTCF and BRD2 (Hi-C), and allows regulatory influence to spread between adjacent genes (single-molecule FISH); BRD4 does not co-localize with CTCF.\",\n      \"method\": \"ChIP-seq, Hi-C, single-molecule mRNA FISH, BRD2 depletion, site-specific CTCF disruption\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genome-wide ChIP-seq, Hi-C, and single-molecule FISH with depletion; multiple orthogonal methods in one study\",\n      \"pmids\": [\"28388437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Brd2 associates with the chromatin insulator CTCF and the cohesin complex to support cis-regulatory enhancer assembly during Th17 cell differentiation; Brd2 binds the transcription factor Stat3 in an acetylation-sensitive manner and facilitates Stat3 recruitment to active enhancers occupied by Irf4 and Batf; Brd4 controls RNA Pol II processivity via cyclin T1/Cdk9 recruitment and Pol II Ser2 phosphorylation—distinct from Brd2's role.\",\n      \"method\": \"ChIP-seq, Co-IP (acetylation-sensitive), Th17 differentiation model with genetic depletion, Pol II Ser2 phosphorylation assay\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq with Co-IP and Pol II phosphorylation assays, replicated independently in same year by complementary study; multiple orthogonal methods in one lab\",\n      \"pmids\": [\"28262505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BRD2 promotes spatial mixing and A/B compartmentalization of active chromatin after cohesin loss; this activity requires BRD2's double bromodomain (acetylated target recognition) and its low-complexity domain (binding partners); BRD4 and cohesin antagonize BRD2 binding to chromatin; polymer simulation supports a BRD2-cohesin interplay model for nuclear topology.\",\n      \"method\": \"Hi-C (cohesin depletion), live-cell imaging, domain mutant analysis, polymer simulation, ChIP-seq\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — Hi-C, live imaging, domain mutagenesis, and polymer modeling; multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"35410381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"H2A.Z.1 monoubiquitylation (H2A.Z.1ub) antagonizes BRD2 at bivalent gene promoters in ESCs; loss of monoubiquitylation results in BRD2 gain at de-repressed promoters, and BRD2 inhibition restores gene silencing at these sites, establishing an antagonistic relationship between H2A.Z.1ub and BRD2 in regulating transcriptional balance at bivalent genes.\",\n      \"method\": \"H2A.Z.1(K3R3) mutant ESCs, quantitative proteomics, BRD2 ChIP, BRD2 inhibitor rescue experiments\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative proteomics, ChIP, and pharmacological rescue in a defined genetic mutant; multiple orthogonal methods\",\n      \"pmids\": [\"26804911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BRD2 is spatially recruited to DNA double-strand breaks (DSBs) via its tandem bromodomains binding to H4 acetylation generated by Tip60/KAT5; BRD2 binding protects H4Ac from deacetylases and allows acetylation to spread ~2 kb flanking the DSB; BRD2 facilitates ZMYND8 recruitment to flanking chromatin, limits L3MBTL1 repressor binding, and promotes 53BP1 binding while limiting end-resection.\",\n      \"method\": \"ChIP at DSBs (laser damage), BRD2 domain mutant analysis, ZMYND8/53BP1 co-localization, bromodomain mutant rescue\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP at DSBs with domain mutants and functional downstream readouts; single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"29018219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HDAC11 suppresses the brown adipose tissue thermogenic program through physical association with BRD2; HDAC11 catalytic activity is required for this suppression and the mechanism depends on BRD2 interaction, as demonstrated by co-immunoprecipitation and cell-based assays.\",\n      \"method\": \"HDAC11 knockout mice, co-immunoprecipitation, cell-based transcriptional assays, ex vivo BAT analysis\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP with knockout phenotype and functional dependence on catalytic activity; single lab, two orthogonal methods\",\n      \"pmids\": [\"30089714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LYAR binds BRD2 through a mechanism not requiring acetyl-lysine-binding bromodomains and recruits BRD2 to rDNA promoters and transcribed regions via upstream binding factor (UBF); BRD2 is required for recruitment of the MYST-type acetyltransferase KAT7 to rDNA, resulting in enhanced local H4 acetylation and increased rRNA synthesis.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-qPCR at rDNA, siRNA knockdown, histone acetylation analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP with ChIP and knockdown functional readout; single lab, two orthogonal methods\",\n      \"pmids\": [\"31504794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BRD2 is required for ACE2 transcription in human lung epithelial cells and cardiomyocytes; BRD2 inhibition reduces endogenous ACE2 expression and blocks SARS-CoV-2 infection in human cells and Syrian hamsters; BRD2 also controls transcription of interferon-stimulated genes induced upon SARS-CoV-2 infection.\",\n      \"method\": \"Targeted CRISPRi screen, BRD2 pharmacological inhibition (ABBV-744), qRT-PCR, viral infection assay, in vivo hamster model\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPRi screen with pharmacological validation in vitro and in vivo; multiple orthogonal approaches across cell types and animal model\",\n      \"pmids\": [\"35027731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BRD2 is the critical BET family mediator of STAT5 transcriptional activity; BRD2 knockdown (but not BRD3 or BRD4) selectively reduces STAT5-dependent (not STAT3-dependent) gene expression in leukemia cells; BRD2 knockdown synergizes with tyrosine kinase inhibitors in inducing apoptosis in STAT5-driven leukemia models.\",\n      \"method\": \"siRNA knockdown of individual BET proteins, STAT5 reporter assays, gene expression analysis, cell viability/apoptosis assays\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — isoform-specific siRNA knockdown distinguishing BRD2 from BRD3/BRD4, functional STAT5 reporter; single lab, two orthogonal methods\",\n      \"pmids\": [\"24435449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Whole-body disruption of Brd2 causes severe obesity with pancreatic islet expansion and hyperinsulinemia but enhanced glucose tolerance; Brd2 normally inhibits beta-cell mitosis and insulin transcription; in adipocytes, Brd2 co-represses PPARγ and inhibits adipogenesis; Brd2 knockdown protects adipocytes from TNF-α-induced insulin resistance.\",\n      \"method\": \"Brd2 knockout mice, 3T3-L1 adipocyte knockdown, insulin secretion assay, metabolic phenotyping\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout and cell-based knockdown with defined metabolic phenotype; single lab, two cellular systems\",\n      \"pmids\": [\"19883376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BRD2 directly binds the cyclin A promoter in primary B cells (ChIP); forced Brd2 expression in B cells expands the B cell compartment and increases cyclin A mRNA/protein levels and S-phase progression in mitogen-stimulated B cells but not T cells; BRD2 is also required for hematopoiesis as shown by Brd2-specific knockdown.\",\n      \"method\": \"Lentiviral overexpression in HSCs with reconstitution, ChIP at cyclin A promoter, siRNA knockdown, cell cycle analysis\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with in vivo reconstitution model and knockdown; single lab, two orthogonal methods\",\n      \"pmids\": [\"24319289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A compound (1a) functions as a molecular glue degrader that drives interaction between BRD2/4 and the E3 ligase adaptor DCAF16 to promote BRD2/4 ubiquitination and degradation; CRISPR knockout of DCAF16 abolishes compound activity.\",\n      \"method\": \"CRISPR/Cas9 knockout screen of >1000 ligase genes, Co-IP of BRD2/4 with DCAF16, cellular degradation assays\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR screen with Co-IP validation demonstrating compound-induced BRD2-DCAF16 interaction; single lab, two orthogonal methods\",\n      \"pmids\": [\"36656921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NMR spectroscopy identified a specific binding site for the ET domains of BRD2 (and BRD4) on KSHV kLANA C-terminal domain; functional studies show oligomerization of kLANA CTD, the basic patch, and the ET binding site are all required for LANA nuclear speckle formation and latent replication.\",\n      \"method\": \"NMR spectroscopy, X-ray crystallography of LANA CTD, kLANA deletion/point mutants in functional replication and speckle assays\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR-identified binding site combined with crystal structure and mutagenesis/functional validation; multiple orthogonal methods in one study\",\n      \"pmids\": [\"24146614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The C-terminal chromatin-binding domain of KSHV LANA-1 is required for interaction with Brd2/RING3, and this same domain is required for LANA-1 functions including binding and replication of viral episomal DNA, transcriptional modulation, and chromatin interaction; deletion mutant analysis maps the minimal interaction region.\",\n      \"method\": \"LANA-1 deletion mutants, Co-IP, episomal replication assay, transcription reporter assay\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — systematic deletion mapping with Co-IP and multiple functional readouts; single lab\",\n      \"pmids\": [\"16227282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BRD2/RING3 (via ET domain) and BRD4S delay S-phase entry (G1 arrest) and increase cyclin E promoter activity when ectopically expressed; KSHV LANA-1 directly interacts with BRD4S C-terminal ET domain and partly releases cells from BRD4S- and BRD2/RING3-induced G1 arrest while reducing BRD4S-mediated cyclin E promoter activity.\",\n      \"method\": \"Ectopic expression in epithelial and B-cell lines, cell cycle FACS, cyclin E promoter reporter assay, Co-IP/domain mapping\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — reporter assays and FACS cell-cycle analysis with Co-IP; single lab, two orthogonal approaches\",\n      \"pmids\": [\"16928768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BRD2 is required for IFN-stimulated H2A.Z eviction at ISG promoters; BRD2 (and GCN5) depletion blocks IFN-driven H2A.Z removal, impairs ISGF3 recruitment, and reduces ISG mRNA expression and antiviral immunity; BRD2 involvement is distinct from INO80 and SWI/SNF.\",\n      \"method\": \"siRNA knockdown of BRD2/GCN5/INO80/SWI-SNF, ChIP for H2A.Z and ISGF3, ISG mRNA quantification, viral infection assay\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific siRNA knockdown with ChIP and functional antiviral readout; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"30240626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BRD2 cooperates with acetylated ELK4 (acetylated at K125) to regulate LAMB3 transcription in colorectal cancer; ELK4 K125 acetylation enhances its interaction with BRD2; JQ1 disrupts ELK4-BRD2 interaction and reduces BRD2 binding to the LAMB3 promoter.\",\n      \"method\": \"Co-IP with acetylation mutants, ChIP at LAMB3 promoter, JQ1 treatment, mutagenesis of ELK4 K125\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP with acetylation mutagenesis and ChIP; single lab, two orthogonal methods\",\n      \"pmids\": [\"32398865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BRD2 silencing (but not BRD3 or BRD4) specifically averts sigma-2 receptor (S2R) up-regulation induced by cholesterol deprivation; endogenous BRD2 co-immunoprecipitates with the transcription-active N-terminal half of SREBP2; ChIP-qPCR shows co-occupancy of BRD2, H3K27ac, and SREBP2 at the S2R gene promoter, revealing a BRD2/SREBP2 cooperative transcriptional mechanism.\",\n      \"method\": \"Isoform-specific siRNA knockdown, Co-IP, ChIP-qPCR\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — isoform-specific knockdown, Co-IP, and ChIP; single lab, three complementary methods\",\n      \"pmids\": [\"33234676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BRD2 is required for TAF3-mediated RNA Pol II initiation at promoters with low H3K4me3 and for R-loop suppression during Pol II elongation; BRD2 and BRD3 function additively, independently, or antagonistically at different promoters; BRD2 also regulates genes critical for embryoid body differentiation by promoter priming in ESCs.\",\n      \"method\": \"Acute BRD2 protein degradation (auxin-inducible degron), ChIP-seq, quantitative proteomics, R-loop assay, BRD2/BRD3 single and double depletion\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — acute protein degradation with genome-wide ChIP-seq and proteomics plus R-loop assay; multiple orthogonal methods in one study\",\n      \"pmids\": [\"35665862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"During pluripotent exit, Brd4 downregulation facilitates enhanced Brd2 occupancy at Nodal gene regulatory elements (NREs); Brd2 (not Brd4) is specifically required for differentiative Nodal-Smad2 signaling; BET proteins engage NREs to promote Nodal signaling and Smad2 developmental responses.\",\n      \"method\": \"Small-molecule screen, ChIP at NREs, targeted BRD2/BRD4 depletion, Smad2 activation assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — ChIP with isoform-specific depletion and Smad2 functional readout; single lab\",\n      \"pmids\": [\"28588073\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BRD2 promotes drug resistance in adult T-cell lymphoblastic lymphoma via the RasGRP1/Ras/ERK signaling pathway; BRD2 and E2F1 co-occupy the RasGRP1 promoter (ChIP), and BRD2 suppresses doxorubicin-induced apoptosis both in vitro and in vivo.\",\n      \"method\": \"ChIP at RasGRP1 promoter, Ras pull-down assay, overexpression/knockdown, xenograft model\",\n      \"journal\": \"Cancer communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — ChIP and Ras activation assay with in vivo xenograft; single lab, two orthogonal methods\",\n      \"pmids\": [\"32459053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Phosphocreatine (PCr) stabilizes BRD2 by inhibiting poly-ubiquitination; PCr outcompetes the E3 ubiquitin ligase SPOP for BRD2 binding, preventing SPOP-mediated BRD2 degradation; disruption of PCr biosynthesis by cyclocreatine leads to BRD2 degradation and decreased transcription of BRD2 target genes involved in chromosome segregation.\",\n      \"method\": \"Co-IP (BRD2-SPOP interaction), ubiquitination assay, cyclocreatine treatment, BRD2 stability assay, mouse GBM models\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with ubiquitination assay and in vivo tumor model; single lab, two orthogonal biochemical methods\",\n      \"pmids\": [\"38563585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Brd2 inhibits adipogenesis via the ERK1/2 signaling pathway; Brd2 overexpression increases ERK1/2 phosphorylation and represses PPARγ/C/EBPα expression; Brd2 knockdown decreases ERK1/2 activity independently of Raf signaling; MEK inhibitor UO126 partly restores adipogenic differentiation in Brd2-overexpressing cells.\",\n      \"method\": \"Overexpression and siRNA knockdown in 3T3-L1 cells, ERK1/2/JNK/p38 phosphorylation assays, MEK inhibitor epistasis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — gain/loss-of-function with kinase epistasis and MEK inhibitor rescue; single lab\",\n      \"pmids\": [\"24194944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BRD2 physically interacts with BRD7 in mammalian cells; the region of BRD2 from amino acids 430–798 is critical for BRD2-BRD7 interaction; BRD2 localizes predominantly to the nucleus in diffuse and dotted patterns, with dotted distribution correlating with apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, subcellular co-localization (GFP), deletion mapping, Hoechst staining\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP with deletion mapping; nuclear localization data correlative for apoptosis, single lab\",\n      \"pmids\": [\"16786191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The growth factor pleiotrophin (Ptn) antagonizes Brd2 during neuronal differentiation by destabilizing Brd2's association with chromatin; Ptn-Brd2 interaction was identified by co-immunoprecipitation; Ptn knockdown reduces neuronal differentiation, while Ptn overexpression antagonizes Brd2 cell-cycle-stimulating activity.\",\n      \"method\": \"Co-immunoprecipitation, chromatin fractionation, Ptn knockdown/overexpression, neuronal differentiation assays, spinal cord and neural crest in vivo models\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP with chromatin fractionation and in vivo developmental validation; single lab, two orthogonal methods\",\n      \"pmids\": [\"24695857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"RUNX2 and BRD2 co-immunoprecipitate and both occupy the RANKL promoter; mechanical strain reduces both RUNX2 and BRD2 occupancy at the RANKL promoter (ChIP) and decreases RANKL expression; strain also down-regulates BRD2 expression; RUNX2 knockdown prevents strain-induced RANKL down-regulation.\",\n      \"method\": \"Co-immunoprecipitation, ChIP at RANKL promoter, four-point bending strain assay, RUNX2 siRNA knockdown\",\n      \"journal\": \"Gene: X\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP and ChIP with knockdown; single lab, correlative mechanosensing context\",\n      \"pmids\": [\"32550554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"p85/RING3 kinase is activated in multiple organs (lung, kidney, brain, liver, heart) after systemic administration of mitogens (EGF, PMA, IL-1β); anti-RING3 antibodies immunoprecipitate the mitogen-responsive p85 kinase activity from lung and brain, establishing that p85 and RING3 are the same enzyme.\",\n      \"method\": \"Autophosphorylation membrane assay, kinase immunoprecipitation from tissue lysates\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — immunoprecipitation kinase assay in vivo; single lab, single method establishing identity of p85 with RING3\",\n      \"pmids\": [\"9528865\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BRD2 is a BET family double-bromodomain protein that reads acetylated histone H4 (preferentially H4K12ac via a homodimeric BD1 structure), associates with hyperacetylated chromatin across transcribed gene bodies, and acts as a transcriptional scaffold by recruiting E2F transcription factors, TBP, and histone acetyltransferases to promote RNA Pol II initiation (via TAF3) and elongation while suppressing R-loops; it co-occupies chromatin with the insulator protein CTCF to enforce topological domain boundaries and compartmentalize the accessible genome, and it coordinates distinct context-specific functions including Th17/Smad2/Nodal signaling, macrophage cytokine gene activation, STAT5-dependent transcription, ACE2/interferon-response gene regulation, DNA double-strand break repair via H4Ac protection, and metabolic gene control in adipocytes and pancreatic β-cells, with its stability regulated by SPOP-mediated ubiquitination (antagonized by phosphocreatine) and its chromatin association modulated by HDAC11, pleiotrophin, and H2A.Z monoubiquitylation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BRD2 is a BET-family double-bromodomain protein that reads acetylated histone H4 and acts as a chromatin-associated transcriptional scaffold and architectural factor [#0, #1]. Its N-terminal bromodomain forms a homodimer with two acetyllysine-binding pockets that specifically recognizes H4 acetylated at Lys12, with hypoacetylated Lys8 binding at the dimer interface to complete recognition [#1, #2]. BRD2 associates along the entire lengths of transcribed genes enriched in H4K5ac/H4K12ac/H3K14ac and enables RNA Pol II to transcribe through nucleosomes in a defined in vitro system, with intrinsic histone chaperone activity [#0]; chromatin recruitment also depends on features of the histone variant H2A.Z and is antagonized by H2A.Z.1 monoubiquitylation at bivalent promoters [#11, #17]. Mechanistically, BRD2 recruits E2F-1/E2F-2 and H4-directed acetyltransferase activity together with TBP to E2F-responsive promoters such as cyclin A to promote cell-cycle gene transcription [#3, #6, #7], and it supports RNA Pol II initiation through TAF3 at promoters with low H3K4me3 while suppressing R-loops during elongation [#32]. Independently of transcriptional readout, BRD2 co-localizes genome-wide with the insulator protein CTCF, which recruits it to enforce topological domain boundaries, and it promotes A/B compartmentalization of active chromatin via its double bromodomain and low-complexity domain in an interplay with cohesin and BRD4 [#14, #16]. BRD2 is required for embryogenesis and neural tube closure, acting upstream of E2F1 to control cell-cycle exit and neuronal differentiation [#9, #10]. Context-specific roles include macrophage inflammatory cytokine gene activation [#12], STAT5-dependent leukemic transcription [#22], Th17 enhancer assembly through CTCF/cohesin and acetylation-sensitive Stat3 binding [#15], ACE2 and interferon-stimulated gene regulation [#21, #29], recruitment to DNA double-strand breaks where it protects Tip60-generated H4Ac and modulates 53BP1/ZMYND8 [#18], and metabolic gene control in adipocytes and pancreatic β-cells [#23]. BRD2 protein stability is governed by SPOP-mediated ubiquitination, which phosphocreatine antagonizes by outcompeting SPOP binding [#35].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established that RING3/BRD2 functions as a nuclear transcriptional activator of cell-cycle genes coupled to E2F and the Rb/Ras axis, defining its earliest mechanistic role.\",\n      \"evidence\": \"reporter transactivation, kinase-dead mutagenesis, E2F co-purification and Rb epistasis; NLS mutagenesis with serum-induced nuclear translocation\",\n      \"pmids\": [\"10965846\", \"10934046\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether transactivation requires a genuine intrinsic kinase activity was not resolved structurally\",\n        \"Direct versus scaffold-mediated E2F engagement not distinguished\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed that BRD2 physically occupies the cyclin A promoter and delivers E2F-1 and H4-acetyltransferase activity, converting the genetic link into a chromatin-recruitment mechanism.\",\n      \"evidence\": \"ChIP at cyclin A promoter, Co-IP, HAT assays in immunopurified complexes, cell-cycle analysis\",\n      \"pmids\": [\"15548137\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Identity of the associated acetyltransferase not defined in this study\",\n        \"Direct contact surface with E2F not mapped\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Resolved the structural basis of acetyllysine reading: BD1 is a homodimer that specifically binds H4K12ac, and BRD2 bridges to the basal machinery via TBP.\",\n      \"evidence\": \"X-ray crystallography of BD1, dimerization assays, reciprocal Co-IP and peptide mapping of BRD2-TBP interaction\",\n      \"pmids\": [\"17148447\", \"17111193\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Physiological consequence of BD1 dimerization on full-length chromatin binding not addressed\",\n        \"Generality of TBP recruitment beyond E2F promoters unknown\"\n      ]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined the genome-wide chromatin behavior and biochemical readout: BRD2 tracks hyperacetylated transcribed gene bodies and supports Pol II transcription through nucleosomes.\",\n      \"evidence\": \"ChIP-seq, defined in vitro transcription reconstitution, histone modification analysis\",\n      \"pmids\": [\"18406326\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Mechanism of intrinsic histone chaperone activity not structurally defined\",\n        \"Functional separation of BRD2 from BRD3 in vivo not established here\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrated an essential, embryo-autonomous developmental requirement and connected BRD2's cell-cycle function to neural fate via E2F1.\",\n      \"evidence\": \"knockout mice with tetraploid complementation, in situ hybridization; later double-mutant E2F1 rescue and metabolic knockout phenotyping\",\n      \"pmids\": [\"19301389\", \"19362612\", \"22885183\", \"19883376\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Tissue-specific transcriptional targets driving neural tube closure not enumerated\",\n        \"Molecular link between BRD2 loss and metabolic phenotypes incomplete\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extended chromatin recruitment beyond H4ac to the histone variant H2A.Z, showing combinatorial targeting that controls specific gene programs.\",\n      \"evidence\": \"nucleosome purification/MS, Co-IP, ChIP, chemical inhibition; H2A.Z.1 monoubiquitylation mutant ESCs with BRD2 ChIP and inhibitor rescue\",\n      \"pmids\": [\"23144632\", \"26804911\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct H2A.Z recognition surface on BRD2 not identified\",\n        \"How monoubiquitylation sterically antagonizes BRD2 binding not resolved\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Mapped functional domain contributions and broadened BRD2's output to alternative splicing and inflammatory cytokine gene activation in macrophages.\",\n      \"evidence\": \"FRAP with domain deletions, transcriptome screen, Co-IP; ChIP at cytokine promoters with genetic hypomorph, siRNA and JQ1\",\n      \"pmids\": [\"24048450\", \"23420887\", \"24319289\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Splicing regulation mechanism (co-transcriptional vs. spliceosome contact) undefined\",\n        \"C-terminal domain binding partners not identified\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed a non-transcriptional architectural role: BRD2 is recruited by CTCF to enforce topological boundaries and prevent regulatory cross-talk, distinguishing it from BRD4.\",\n      \"evidence\": \"ChIP-seq, Hi-C, single-molecule FISH with BRD2 depletion and CTCF disruption; Th17 enhancer assembly with cohesin and Stat3\",\n      \"pmids\": [\"28388437\", \"28262505\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether BRD2 stabilizes CTCF/cohesin or acts as an independent insulator not fully separated\",\n        \"Direct CTCF-BRD2 contact surface not mapped\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Implicated BRD2 in DNA double-strand break repair by reading Tip60-generated H4 acetylation to protect the mark and organize downstream repair factors.\",\n      \"evidence\": \"ChIP at laser-induced DSBs, bromodomain mutant rescue, ZMYND8/53BP1 co-localization\",\n      \"pmids\": [\"29018219\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single-lab study without independent replication\",\n        \"Quantitative impact on repair pathway choice not established\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Unified BRD2's architectural function mechanistically, showing it drives active-compartment mixing through its double bromodomain and low-complexity domain in antagonism with cohesin/BRD4, and elevated its biomedical role to ACE2/ISG control.\",\n      \"evidence\": \"Hi-C after cohesin depletion, live imaging, domain mutagenesis, polymer simulation; CRISPRi/pharmacological ACE2 and SARS-CoV-2 in vitro and hamster model; auxin-degron ChIP-seq for TAF3/R-loop functions\",\n      \"pmids\": [\"35410381\", \"35027731\", \"35665862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How LCD-mediated partner binding integrates with bromodomain reading is not resolved at atomic level\",\n        \"Direct versus indirect control of the ACE2 promoter not fully dissected\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified post-translational control of BRD2 abundance via SPOP-mediated ubiquitination antagonized by phosphocreatine, linking metabolism to BRD2-dependent gene expression.\",\n      \"evidence\": \"Co-IP of BRD2-SPOP, ubiquitination assays, cyclocreatine treatment, glioblastoma mouse models\",\n      \"pmids\": [\"38563585\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single-lab biochemistry without independent confirmation\",\n        \"SPOP degron within BRD2 not precisely mapped\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BRD2 integrates acetyl-lysine reading, H2A.Z recognition, CTCF/cohesin association, and low-complexity-domain interactions into a single recruitment logic that selects between transcriptional, splicing, repair, and architectural outputs remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No structural model couples bromodomain reading to LCD-driven compartmentalization\",\n        \"Rules distinguishing BRD2-specific from BRD3/BRD4 target selection not established\",\n        \"Whether reported context-specific transcription-factor partnerships share a common recruitment mechanism is unknown\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [0, 1, 2, 18]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3, 6, 7, 32]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [3, 6, 7, 14]},\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 37]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [0, 14, 16]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 3, 6, 32]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [3, 6, 10, 24]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0, 11, 14, 16, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [12, 15, 22, 29]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [9, 10, 33]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"E2F1\", \"TBP\", \"CTCF\", \"STAT5\", \"STAT3\", \"H2A.Z\", \"SPOP\", \"BRD7\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":8,"faith_total":8,"faith_pct":100.0}}